Edgar Filing: ARRAY BIOPHARMA INC - Form 4

ARRAY B Form 4 April 05, 20	IOPHARMA INC									
FORM Check ti if no low subject Section Form 4 Form 5 obligati may co <i>See</i> Inst 1(b).	M 4 UNITED his box nger to 16. or or filed pur Section 17(AENT O rsuant to S (a) of the 1	Wa F CHAN Section I Public U	Ishington NGES IN SECUI 16(a) of th Utility Hol	, D.C. 2 BENE RITIES ne Secu ding Co	20549 FICIAL O'	E COMMISSIO WNERSHIP OI nge Act of 1934, of 1935 or Secti 1940	N OMB Number: Expires: Estimated burden hou response	urs per	, 5
(Print or Type 1. Name and MOORE J	2. Issuer Name and Ticker or Trading Symbol ARRAY BIOPHARMA INC [ARRY]			5. Relationship of Reporting Person(s) to Issuer (Check all applicable)						
(Last) 3200 WAI	(First) (Middle)	3. Date of Earliest Transaction (Month/Day/Year) 03/31/2011			n	Director I0% Owner X_ Officer (give title Other (specify below) VP, General Counsel			
BOULDEI	4. If Amendment, Date Original Filed(Month/Day/Year)			6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting Person						
(City)	(State)	(Zip)	Tab	le I - Non-l	Derivativ	ve Securities A	Acquired, Disposed	of, or Beneficia	lly Owned	
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	Execution any	Date, if	3. Transactio Code (Instr. 8) Code V	Dispose (Instr. 3	(A) or d of (D) , 4 and 5) (A) or	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
Reminder: Re	eport on a separate line	e for each cl	ass of sec	urities bene	Pers info requ disp	ons who res rmation cont ired to resp	or indirectly. spond to the colle tained in this form ond unless the fo ntly valid OMB co	n are not rm	SEC 1474 (9-02)	

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of	2.	3. Transaction Date	3A. Deemed	4.	5. Number of	6. Date Exercisable and	7. Title and Amount of
Derivative	Conversion	(Month/Day/Year)	Execution Date, if	Transacti	orDerivative	Expiration Date	Underlying Securities
Security	or Exercise		any	Code	Securities	(Month/Day/Year)	(Instr. 3 and 4)

8 L S

Edgar Filing: ARRAY BIOPHARMA INC - Form 4

(Instr. 3)	Price of Derivative Security		(Month/Day/Year)	(Instr. 8)	Acquired or Dispose (D) (Instr. 3, 4 and 5)	ed of				
				Code V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	\$ 3.06	03/31/2011		A	60,000		<u>(1)</u>	03/31/2021	Common Stock	60,000
Stock Option (Right to Buy)	\$ 3.06	03/31/2011		А	1,250		(2)	03/31/2021	Common Stock	1,250

Reporting Owners

Reporting Owner Name / Address	Relationships							
	Director	10% Owner	Officer	Other				
MOORE JOHN R 3200 WALNUT STREET BOULDER, CO 80301			VP, General Counsel					
Signatures								
R. Michael Carruthers, attorney Person	9 04/05/2011	l						
<u>**</u> Signature of Report	Date							

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The option vests in four equal annual installments beginning March 4, 2012.
- (2) The option vests in four equal annual installments beginning September 23, 2012.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

(